A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Active, not recruiting · NCT06628310 · Registry updated 2026-07-21

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma	Active, not recruiting	Phase 2	2026-07-21		NCT06628310

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AbbVie	340

49 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
AdventHealth Orlando /ID# 268561	Orlando	United States	1
Aichi Cancer Center /ID# 268124	Nagoya	Japan	1
Algemeen Ziekenhuis klina /ID# 268754	Brasschaat	Belgium	1
Barts Health NHS Trust /ID# 270796	London	United Kingdom	1
Beijing Cancer Hospital /ID# 268455	Beijing	China	1
Cancer Hospital Chinese Academy of Medical Sciences(Langfang) /ID# 277479	Langfang	China	1
Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 268763	Montreal	Canada	1
China Medical University Hospital /ID# 267667	Taichung	Taiwan	1
CHU de Liege /ID# 270223	Liège	Belgium	1
City Of Hope - Atlanta /ID# 280646	Newnan	United States	1
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630	Irvine	United States	1
City of Hope National Medical Center /ID# 268690	Duarte	United States	1
Complexo Hospitalario Universitario de Ourense /ID# 270042	Ourense	Spain	1
Duke University Medical Center /ID# 268186	Durham	United States	1
Hadassah Medical Center-Hebrew University /ID# 267753	Jerusalem	Israel	1
Haematologisch-Onkologische Praxis Eppendorf /ID# 268024	Hamburg	Germany	1
Harbin Medical University Cancer Hospital /ID# 268452	Harbin	China	1
Hattiesburg Clinic /ID# 268572	Hattiesburg	United States	1
Hospital Clinico Universitario de Valencia /ID# 270040	Valencia	Spain	1
Hospital General Universitario Gregorio Maranon /ID# 270037	Madrid	Spain	1
Hospital Universitario de Navarra /ID# 270119	Pamplona	Spain	1
Jewish General Hospital /ID# 268413	Montreal	Canada	1
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267672	Kaohsiung City	Taiwan	1
Krankenhaus Nordwest /ID# 268462	Frankfurt am Main	Germany	1
Linkou Chang Gung Memorial Hospital /ID# 267668	Taoyuan City	Taiwan	1

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Clinical trials

Organizations

Research sites